Merck’s Co-Developed Vaccine Candidate, Against Hospital Infection MRSA, Suddendly Looks Iffy

After a relatively quiet news weekend on all fronts Merck, the notoriously difficult to combat hospital born infection known as MRSA may remain in the wild for yet another generation, now. Per a Reuters report:

. . . .Patient enrollment into a clinical trial of an experimental vaccine from Intercell (ICEL.VI) and Merck & Co (MRK.N) against the hospital infection MRSA has been put on hold. . . .

The study’s independent data monitoring committee (DMC) recommended that no more patients be enrolled into the Phase II/III trial while experts assess the vaccine’s benefits against its risks.

Investors interpreted the development as a major setback for the key experimental product and shares in the Austrian biotech group [called Intercell] lost more than a fifth of their value on Monday. . . .

Intercell shares have recovered some of the ground lost earlier in the European trading day, but this development would still seem to suggest that a MRSA vaccine is still an elusive goal. We will keep you posted.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s